Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,293,496 papers from all fields of science
Search
Sign In
Create Free Account
EMD 121974
Known as:
EMD-121974
, EMD121974
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Cilengitide
Cyclic Peptides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Differential growth inhibition of cerebral metastases by anti-angiogenic compounds.
Daniel Martin
,
Ortrud Uckermann
,
+7 authors
M. Kirsch
Anticancer Research
2014
Corpus ID: 34261713
BACKGROUND The formation of brain metastases is intrinsically linked to concomitant angiogenesis. The purpose of the present…
Expand
2013
2013
Gene expression profiling of the anti-glioma effect of Cilengitide
Manabu Onishi
,
K. Kurozumi
,
+7 authors
I. Date
SpringerPlus
2013
Corpus ID: 8429461
Cilengitide (EMD121974), an inhibitor of the adhesive function of integrins, demonstrated preclinical efficacy against malignant…
Expand
2012
2012
A phase I study of continuous infusion cilengitide in patients with solid tumors
Peter H. O’Donnell
,
S. Undevia
,
+4 authors
M. Ratain
Investigational new drugs
2012
Corpus ID: 23878686
SummaryBackground: Cilengitide (EMD121974) is a cyclized pentapeptide that is a potent and selective integrin antagonist which…
Expand
2011
2011
L’inhibiteur d’intégrines Cilengitide : un nouveau principe actif en neuro-oncologie
P. Leblond
,
S. Meignan
,
F. L. Tinier
,
Ullrich Bethe
,
A. Lansiaux
2011
Corpus ID: 227103786
Resume Ces dernieres annees ont vu l’essor des strategies antiangiogeniques dans le traitement des cancers. Parmi elles, le…
Expand
Review
2011
Review
2011
[The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
P. Leblond
,
S. Meignan
,
F. le Tinier
,
U. Bethe
,
A. Lansiaux
Bulletin du Cancer
2011
Corpus ID: 36124804
Last years saw the development of anti-angiogenic strategies in the treatment of cancers. Cilengitide (EMD121974; Merck KGaA…
Expand
Review
2007
Review
2007
Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009
D. Reardon
,
K. Fink
,
+7 authors
T. Mikkelsen
2007
Corpus ID: 70478121
2002 Background: Our phase IIa study evaluated the safety, toxicity, and clinical activity of the cyclic RGD pentapeptide…
Expand
2007
2007
Distinctive role of integrin-mediated adhesion in TNF-induced PKB/Akt and NF-κB activation and endothelial cell survival
G. Bieler
,
M. Hasmim
,
+10 authors
C. Rüegg
Oncogene
2007
Corpus ID: 28551294
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine exerting pleiotropic effects on endothelial cells. Depending on the…
Expand
2007
2007
Thérapies moléculaires ciblées
Y. Loriot
ONCOLOGIE
2007
Corpus ID: 6600291
Parmi les confirmations, celle du bévacizumab en première ligne métastatique du cancer du rein présenté dans l’article de C. Th…
Expand
Highly Cited
2006
Highly Cited
2006
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
K. Beekman
,
A. Colevas
,
+8 authors
M. Hussain
Clinical Genitourinary Cancer
2006
Corpus ID: 26453160
Two randomized trials demonstrated an improvement in survival with docetaxel-based chemotherapy for patients with metastatic…
Expand
Highly Cited
2005
Highly Cited
2005
Biological and molecular properties of a new αvβ3/αvβ5 integrin antagonist
L. Belvisi
,
T. Riccioni
,
+16 authors
C. Pisano
Molecular Cancer Therapeutics
2005
Corpus ID: 21279229
The aim of the present study was to identify specific αvβ3/αvβ5 integrin antagonists active on tumor-induced angiogenesis. To…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE